The global needle-free injection systems market is projected to generate $466.2 million revenue in 2030, advancing at a CAGR of 13.3% during 2021–2030. This can be attributed to the rise in the number of diabetic patients across the globe and the technical advancements in healthcare systems. Moreover, the surging prevalence of chronic diseases and the increasing demand for self-medication are propelling the market growth.
The liquid-based category accounted for the largest revenue share, around 70%, in 2021 and it is further expected to maintain its dominance during the forecast period. This is due to its high-speed jet, which punctures the skin without using a needle to administer medications. Furthermore, liquid-based injectors have been widely utilized to administer a variety of macromolecules, such as vaccines and insulin, as well as tiny molecules including anesthetics and antibiotics.
Moreover, fillable needle-free injectors held a significant revenue share in 2021. This is because these are highly efficient injection technologies utilized for the administration of medicines intramuscularly, subcutaneously, and intradermally. Also, these injectors can be used multiple times for multiple administrations.
Based on application, the insulin delivery category is expected to witness the fastest growth in the market during the forecast period. This can be attributed to the extensive use of needle-free injectors that are more effective and produce less pain and anxiety than traditional needle injectors. Moreover, increasing prevalence of diabetes is playing pivotal role in growth of the market.
On the other hand, the vaccine delivery category accounts largest market share. This is ascribed to the growing incidences of chronic and contagious diseases, which have increased the demand for vaccination in recent years, and the increasing need for patient-focused treatment, across the world.
Geographically, the APAC needle-free injection systems market is projected to record the highest CAGR, of around 14%, during 2021–2030. This can be primarily due to the growing healthcare infrastructure, rising disposable income, and increasing rate of vaccinations in the region. Whereas, North America is the largest revenue contributor to the market, and is projected to witness the same trend during the forecast period as well. This is attributed to the high level of research and development in needle-free injection technology, as well as the high prevalence of diabetes and chronic diseases, which raise the adoption rates of needle-free injectors.
Key players have been engaged in clinical trials and partnerships to gain a competitive edge in the market. For instance, in December 2021, PharmaJet partnered with Nykode Therapeutics to begin phase-1 or 2 clinical trials to address emerging SARS-CoV-2 variants. The DNA-based medicine would be administered intramuscularly in the clinical trial by using the PharmaJet Stratis Needle-free Injection System.
Similarly, in August 2021, Zydus Cadila partnered with PharmaJet Inc. to start the emergency use authorization process for the world's first plasmid DNA COVID-19 vaccine.
Some of the major players in the needle-free injection systems market include Portal Instruments Inc., Inovio Pharmaceuticals Inc., INJEX Pharma, National Medical Products Inc., PenJet Corporation, and PharmaJet Inc.